Related Experiment Video

Updated: Nov 29, 2025

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

4.1K

Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs

Weiguo Xiang, Shaomeng Wang

    Journal of Medicinal Chemistry
    |November 18, 2020
    PubMed

    Insights

    Researchers discovered CG416 and CG428, potent proteolysis-targeting chimera (PROTAC) degraders that selectively target TRKA. These compounds are valuable tools for cancer research and offer promise for future drug development.

    Area of Science:

    • Oncology
    • Medicinal Chemistry
    • Molecular Biology

    Background:

    • Tropomyosin receptor kinases (TRKs) are crucial in cancer development and represent key therapeutic targets.
    • Developing selective inhibitors for TRK family members (TRKA, TRKB, TRKC) is essential for effective cancer treatment.

    Purpose of the Study:

    • To discover and characterize novel small-molecule proteolysis-targeting chimera (PROTAC) degraders targeting TRKs.
    • To evaluate the selectivity and potency of new PROTAC compounds against TRKA, TRKB, and TRKC.

    Main Methods:

    • Design and synthesis of novel PROTAC molecules.
    • Biochemical and cellular assays to assess target engagement and degradation.
    • Selectivity profiling across TRK family members.

    Main Results:

    • Identification of CG416 and CG428 as potent PROTAC degraders.
    • Demonstrated high selectivity of CG416 and CG428 for TRKA over TRKB and TRKC.
    • Validation of CG416 and CG428 as effective research tools for in vitro and in vivo studies.

    Conclusions:

    • CG416 and CG428 represent a significant advancement in TRK-targeted cancer therapy development.
    • These compounds serve as valuable research tools for further investigation of TRK signaling in cancer.
    • The discovered PROTACs hold promise as lead compounds for optimizing future cancer therapeutics.

    More Related Videos

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

    Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

    Published on: September 19, 2018

    8.2K
    Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

    Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

    Published on: May 15, 2019

    13.5K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.2K
    Receptor Tyrosine Kinases01:26

    Receptor Tyrosine Kinases

    Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
    16.7K
    Enzyme-linked Receptors01:00

    Enzyme-linked Receptors

    Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
    Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
    83.6K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    4.8K
    Transducer Mechanism: Enzyme-Linked Receptors01:27

    Transducer Mechanism: Enzyme-Linked Receptors

    Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
    Major types that are helpful drug targets include:
    3.6K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    4.2K